PTC Therapeutics Acquires ST-920 to Enhance Rare Disease Treatment Options

PTC Therapeutics Expands Its Portfolio with ST-920

PTC Therapeutics, Inc. recently announced a strategic move designed to bolster its position in treating rare diseases. By acquiring ST-920, a BLA-stage gene therapy developed for Fabry disease, PTC is further cementing its commitment to providing innovative solutions for patients in need. This acquisition will allow PTC to utilize its existing regulatory and commercial frameworks, which are crucial for expediting the launch of this new therapy.

The deal, which involved bidding for ST-920 from Sangamo Therapeutics during a bankruptcy auction, comes with an initial payment of $111 million, plus an additional potential $100 million tied to achieving specific regulatory milestones. PTC anticipates completing the rolling BLA submission for ST-920 in the fourth quarter of 2026, positioning the company for a possible commercial launch in 2027. The drug's promising safety profile and long-term clinical benefits are expected to drive interest in its approval.

Understanding Fabry Disease

Fabry disease is a rare, progressive genetic disorder characterized by a deficiency of the alpha-galactosidase A (α-Gal A) enzyme due to mutations in the GLA gene. This deficiency leads to harmful amounts of a fatty substance, globotriaosylceramide (Gb3), building up in blood vessels and various organs, resulting in a range of severe symptoms including kidney failure, heart complications, gastrointestinal issues, and chronic pain. It is estimated that around 11,000 individuals in the U.S. are affected by Fabry disease, with similar prevalence rates in other markets.

The Promise of ST-920

Designed as a one-time administered AAV gene therapy, ST-920 aims to enhance the body’s ability to produce α-Gal A enzyme, aiming for long-term decreases in Gb3 levels in patients. This innovative approach could subvert the need for chronic enzyme replacement therapy (ERT), which has been the standard treatment for this disorder. Clinical data from the Phase 1/2 STAAR study has shown meaningful improvements in renal function—specifically an annualized estimated glomerular filtration rate (eGFR)—and a favorable impact on patients’ overall health and quality of life.

One of the key differentiators of ST-920 is its demonstrated durability; the enhancements in enzyme activity have been sustained for over four years in early treated patients. Additionally, the therapy is designed without the necessity for long-term immunosuppression, which can complicate treatment and recovery for patients.

Regulatory Perspectives and Future Plans

The company plans to submit the BLA based on initial clinical endpoints emphasizing eGFR outcomes at 52 weeks, aligning its strategy with FDA guidance. In parallel, PTC will seek regulatory approval beyond the United States, relying on its already established global infrastructure for rare diseases.

Matthew B. Klein, M.D., Chief Executive Officer of PTC, remarked, “This transaction advances our strategy of leveraging our accomplished existing rare disease global commercial infrastructure to accelerate revenue growth both in the short- and intermediate-term.” He expressed confidence in the capability of the company’s teams to bring ST-920 to those who would benefit from it.

As the acquisition process moves forward, PTC awaits final confirmations needed for the completion of the deal, which is projected to be finalized in late Q3 or early Q4 of 2026. A conference call is scheduled for later today, where it will address further details regarding this significant expansion of their rare disease portfolio.

Conclusion

PTC Therapeutics continues to position itself as a leader in rare disease management, leveraging its robust clinical and commercial frameworks to enhance treatment landscapes for conditions that have historically been underserved. With the acquisition of ST-920, PTC hopes to offer a transformative therapy for individuals suffering from Fabry disease, ultimately improving patient outcomes and quality of life.